Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The MSD Business Development & Partnering team have been shortlisted in the PraxisAuril and UK Research and Innovation (UKRI) 2019 Knowledge Exchange Awards, in the category of 'Knowledge Exchange Team of the Year'.

The Knowledge Exchange (KE) awards are a new initiative organised by PraxisAuril, the UK’s world-leading professional association for KE practitioners, to celebrate the contribution of KE professionals in enabling and facilitating the societal and economic impact of research. Sponsored by UKRI, the KE Awards recognise and celebrate the people behind the best KE achievements.

The MSD Business Development team have been shortlisted as finalists in the 'KE Team of the Year' category, which recognises a KE team who have excelled in delivering excellent service and value to their institution. Entries are judged on the success of the team including value added, relationships built, teamwork and challenges overcome. The other finalists in the category are the University of Liverpools' Consultancy Team and the University of Birminghams' Business Engagement Team.

The University of Oxford has also been shortlisted in two other categories:

The winners will be announced at the PraxisAuril conference on the evening of Thursday 13 June 2019.

 

About the MSD BUSINESS DEVELOPMENT TEAM

Over the last 8.5 years, the Business Development and Partnering Team within the Medical Sciences Division at Oxford has grown to 13 members and secured over £58M in industry investment through strategic partnerships. The team build and manage multi-year alliances with 14 companies; support major co-location initiatives with key strategic partners; foster a live pipeline of ~70 mature project development discussions, involving 35 companies and provide dedicated management of industry engagement for the NHS through close association with Oxford’s Biomedical Research Centre.

Some of the key relationships that the team have built, supported and enabled are with Novo Nordisk, Celgene, Bayer HealthCare, Elysium Health and Pfizer. Recently the introduction of a dedicated team member to develop our SME engagement strategy has been pivotal in utilising and creating new models to engage effectively with this set of unique companies.

We develop Fellowship schemes as a model for sustaining long-term engagement with international companies including UCB, Celgene, Novo Nordisk and Elysium, and have shared our experiences at international conferences. Additionally, to drive KE and networking we set up an Oxford Industry Fellows Network (over 50 Industry-sponsored Fellows and postdoctoral researchers) to offer opportunities for industry to train fellows, and for fellows to build their networks.

Our Experts in Residence scheme has driven KE in digital health (iWantGreatCare, IBM, Frog Design), surgical technologies (Koli Inc), med tech regulation (OrganOx), drug discovery and development (Evotech, GSK) and continues to grow.

As a large and disperse division with over 3000 researchers, size doesn’t always work to our advantage and can be a barrier to industry interaction. Our team successfully helps companies navigate the division and we have also found the balance between being visible, but also prioritising relationships where we can add most value.

Find out more about the MSD Business Development Team

 

 

Similar stories

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.